<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101308769</journal-id>
<journal-id journal-id-type="pubmed-jr-id">33486</journal-id>
<journal-id journal-id-type="nlm-ta">Semin Immunopathol</journal-id>
<journal-id journal-id-type="iso-abbrev">Semin Immunopathol</journal-id>
<journal-title-group>
<journal-title>Seminars in immunopathology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1863-2297</issn>
<issn pub-type="epub">1863-2300</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30298433</article-id>
<article-id pub-id-type="pmc">6500089</article-id>
<article-id pub-id-type="doi">10.1007/s00281-018-0716-7</article-id>
<article-id pub-id-type="manuscript">NIHMS1022546</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The microgenderome revealed: sex differences in bidirectional interactions between the microbiota, hormones, immunity and disease susceptibility</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Vemuri</surname>
<given-names>Ravichandra</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sylvia</surname>
<given-names>Kristyn E.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Klein</surname>
<given-names>Sabra L.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Forster</surname>
<given-names>Samuel C.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Plebanski</surname>
<given-names>Magdalena</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eri</surname>
<given-names>Raj</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Flanagan</surname>
<given-names>Katie L.</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1575-1953</contrib-id>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>School of Health Sciences, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia</aff>
<aff id="A2"><label>2</label>The W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA</aff>
<aff id="A3"><label>3</label>Microbiota and Systems Biology Laboratory, Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Melbourne, Victoria, Australia</aff>
<aff id="A4"><label>4</label>Department of Molecular and Translational Sciences, Monash University, Melbourne, Victoria, Australia</aff>
<aff id="A5"><label>5</label>School of Health and Biomedical Science, RMIT University, Melbourne, Victoria, Australia</aff>
<aff id="A6"><label>6</label>Department of Immunology and Pathology, Monash University, Melbourne, Victoria, Australia</aff>
<author-notes>
<corresp id="CR1">Katie L. Flanagan, <email>katie.flanagan@ths.tas.gov.au</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P35"><bold>Conflict of interest</bold> The authors declare that they have no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>26</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>08</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>04</day>
<month>5</month>
<year>2019</year>
</pub-date>
<volume>41</volume>
<issue>2</issue>
<fpage>265</fpage>
<lpage>275</lpage>
<!--elocation-id from pubmed: 10.1007/s00281-018-0716-7-->
<abstract id="ABS1">
<p id="P1">Sex differences in immunity are well described in the literature and thought to be mainly driven by sex hormones and sex-linked immune response genes. The gastrointestinal tract (GIT) is one of the largest immune organs in the body and contains multiple immune cells in the GIT-associated lymphoid tissue, Peyer’s patches and elsewhere, which together have profound effects on local and systemic inflammation. The GIT is colonised with microbial communities composed of bacteria, fungi and viruses, collectively known as the GIT microbiota. The GIT microbiota drives multiple interactions locally with immune cells that regulate the homeostatic environment and systemically in diverse tissues. It is becoming evident that the microbiota differs between the sexes, both in animal models and in humans, and these sex differences often lead to sex-dependent changes in local GIT inflammation, systemic immunity and susceptibility to a range of inflammatory diseases. The sexually dimorphic microbiome has been termed the ‘microgenderome’. Herein, we review the evidence for the microgenderome and contemplate the role it plays in driving sex differences in immunity and disease susceptibility. We further consider the impact that biological sex might play in the response to treatments aimed at manipulating the GIT microbiota, such as prebiotics, live biotherapeutics, (probiotics, synbiotics and bacteriotherapies) and faecal microbial transplant. These alternative therapies hold potential in the treatment of both psychological (e.g., anxiety, depression) and physiological (e.g., irritable bowel disease) disorders differentially affecting males and females.</p>
</abstract>
<kwd-group>
<kwd>Adaptive immunity</kwd>
<kwd>Innate immunity</kwd>
<kwd>Sex differences</kwd>
<kwd>Sex hormones</kwd>
<kwd>Probiotics</kwd>
<kwd>Faecal microbiota transplant</kwd>
<kwd>Bacteriotherapy</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>